Clinical Demand ImmuKnow is FDA-cleared and deployed in organ transplant centers to measure cell-mediated immunity in immunosuppressed patients, indicating ongoing demand for immune monitoring diagnostics.

Regulatory Trust ISO 13485 and ISO 9001 certifications, along with CMDCAS alignment, suggest reliability and quality assurance that can reassure potential hospital and research buyers seeking compliant diagnostic solutions.

Global Patents Patents in the US and Australia with pending filings in Europe, Canada, and Japan indicate defensible technology and potential for international expansion opportunities.

Revenue Range Annual revenue in the 10 to 25 million USD range signals a mid-market biotech supplier with room for up-sell to larger labs, transplant centers, and multi-site deployments.

Strategic Partnerships SBIR-funded immune monitoring method development and a management team with deep experience in diagnostics point to potential collaboration opportunities with defense research programs, academia, and hospitals for expanded applications.